Veno-Occlusive Disease (Sinusoidal obstruction syndrome)

1. Executive Overview: Understanding Veno-Occlusive Disease (VOD/SOS)

Veno-Occlusive Disease (VOD), clinically referred to as Sinusoidal Obstruction Syndrome (SOS), is a life-threatening hepatic complication characterized by the occlusion of the terminal hepatic venules. It is most commonly associated with high-dose chemotherapy or total body irradiation (TBI) administered prior to Hematopoietic Stem Cell Transplantation (HSCT).

Clinically, VOD/SOS manifests through a triad of weight gain, ascites, and jaundice. Due to the high mortality rate associated with severe cases—often exceeding 80% if multi-organ failure (MOF) occurs—early recognition and intervention are critical. This guide provides an authoritative overview of the pathophysiology, diagnostic standards, and current therapeutic modalities for clinicians and patients seeking a deep understanding of this complex condition (ICD-10: K76.5).

2. Pathophysiology, Etiology, and Risk Factors

The Pathophysiological Mechanism

The pathogenesis of VOD/SOS begins with the toxic injury to the sinusoidal endothelial cells (SECs) in the liver. When these cells are damaged by chemotherapeutic agents or radiation, they undergo a necrotic process and detach from the space of Disse.

This cellular debris, combined with the release of pro-inflammatory cytokines, leads to:
1. Endothelial Activation: SECs activate and express adhesion molecules.
2. Micro-thrombosis: The release of pro-coagulant factors leads to the formation of fibrin deposits within the sinusoids.
3. Venular Occlusion: The congestion backs up into the central veins, causing post-sinusoidal portal hypertension, hepatomegaly, and liver cell necrosis due to ischemia.

Etiology and Risk Factors

While HSCT is the primary driver, other causes include the ingestion of pyrrolizidine alkaloids (found in certain herbal teas) and certain medications like azathioprine.

Key Risk Factors for HSCT-Associated VOD/SOS:
* Patient-Related: Pre-existing liver disease (hepatitis, cirrhosis), iron overload, and older age.
* Transplant-Related: Use of mismatched or unrelated donors, and history of prior HSCT.
* Drug-Related: Use of busulfan, cyclophosphamide, or gemtuzumab ozogamicin.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of VOD/SOS typically occurs within the first 21 to 30 days post-HSCT. The hallmark symptoms are often subtle at onset but progress rapidly.

The Classic Triad

1. Weight Gain: Often due to fluid retention and ascites. A daily gain of >2% of baseline body weight is a red flag.
2. Ascites: Resulting from portal hypertension and sodium retention.
3. Jaundice: Hyperbilirubinemia resulting from the impaired excretion of bilirubin by the damaged liver.

Secondary Symptoms

• Hepatomegaly: Often accompanied by right upper quadrant (RUQ) abdominal pain.
• Renal Impairment: Reduced urine output as the disease progresses to hepatorenal syndrome.
• Encephalopathy: In late-stage, severe cases, due to the buildup of ammonia and toxins.

4. Standard Diagnostic Evaluation & Workup

Diagnosis is primarily clinical, supported by standardized criteria such as the Modified Seattle or Baltimore criteria.

Diagnostic Criteria

• Baltimore Criteria: Presence of hyperbilirubinemia (≥2 mg/dL) plus two of the following: hepatomegaly, ascites, or unexplained weight gain, within 21 days post-HSCT.
• Modified Seattle Criteria: Presence of at least two of the following: jaundice, ascites, or weight gain/hepatomegaly, occurring within 20 days post-transplant.

Diagnostic Workup

• Liver Function Tests (LFTs): Elevated bilirubin, ALT/AST, and alkaline phosphatase.
• Coagulation Profile: Monitoring for Protein C deficiency, which is a sensitive biomarker for endothelial injury.
• Imaging:
  • Doppler Ultrasound: The gold standard for assessing portal venous flow. It typically shows reversal of flow (hepatofugal flow) or loss of portal vein pulsatility.
  • CT/MRI: Used to rule out other causes of hepatomegaly or biliary obstruction, though they are rarely diagnostic for VOD itself.
• Liver Biopsy: Rarely performed due to the high risk of hemorrhage in thrombocytopenic transplant patients. It is reserved for cases where the diagnosis remains ambiguous.

5. Therapeutic Interventions

Management is centered on supportive care, fluid management, and specific pharmacotherapy.

Pharmacotherapy

• Defibrotide: The only FDA-approved medication for the treatment of severe hepatic VOD/SOS with renal or pulmonary dysfunction. It acts as an adenosine receptor agonist, promoting fibrinolysis and stabilizing the endothelial cell membrane.
• Supportive Care:
  • Fluid Management: Careful monitoring of intake/output; loop diuretics may be used cautiously.
  • Pain Management: Avoiding hepatotoxic analgesics.
  • Renal Support: If hepatorenal syndrome develops, CRRT (Continuous Renal Replacement Therapy) may be required.

Surgical/Invasive Interventions

• Transjugular Intrahepatic Portosystemic Shunt (TIPS): Occasionally used in refractory cases to decompress the portal system, though this carries high risks in the post-transplant population.

Lifestyle and Long-term Management

Patients who recover must undergo long-term surveillance for chronic liver disease. Alcohol avoidance and strict medication reconciliation are mandatory to prevent further hepatic insult.

6. Frequently Asked Questions (FAQ)

1. Is Veno-Occlusive Disease always fatal?
No, but it is serious. With modern treatments like Defibrotide and early intervention, survival rates have improved significantly, though mortality remains high in severe cases with organ failure.

2. How soon after a bone marrow transplant does VOD appear?
It typically appears within the first three weeks (21 days) post-transplant, though it can occasionally manifest later.

3. What is the role of ultrasound in diagnosing VOD?
Ultrasound is used to measure portal vein flow. A reversal of blood flow (hepatofugal) is a classic, albeit late, sign of severe VOD.

4. Can VOD be prevented?
Yes, clinical protocols often use prophylactic Ursodeoxycholic acid (Ursodiol) in high-risk patients to protect the bile ducts and stabilize hepatocytes.

5. Why is a liver biopsy avoided?
Patients undergoing transplant are often severely thrombocytopenic (low platelet counts). A biopsy carries a high risk of life-threatening internal bleeding.

6. Does VOD only happen to transplant patients?
While most common in HSCT, it can be caused by certain toxins, radiation therapy, or idiosyncratic reactions to specific medications.

7. What is Defibrotide?
Defibrotide is a complex mixture of single-stranded oligodeoxyribonucleotides that helps restore the protective properties of the endothelial lining of the liver.

8. Is jaundice always present in VOD?
Jaundice is a hallmark sign, but in early or mild cases, it may not be the first symptom. Unexplained weight gain is often the earliest clinical indicator.

9. Can VOD lead to kidney failure?
Yes. As the liver becomes congested, it can trigger hepatorenal syndrome, where the kidneys fail due to impaired blood flow and systemic inflammatory changes.

10. What is the long-term outlook for a VOD survivor?
Most patients who recover from VOD do not suffer from long-term liver failure, but they require regular follow-ups with a hepatologist to monitor for secondary complications like portal hypertension.

Disclaimer: This guide is for educational purposes only and does not constitute medical advice. If you suspect you or a loved one is experiencing symptoms of Veno-Occlusive Disease, contact your transplant team or seek emergency medical care immediately.